Glycotope Biotechnology Expands GMP Production Facility to 11 kg Antibody per Year

08-Apr-2011 - Germany

Glycotope Biotechnology GmbH has initiated the setup of further clean room facilities as a first step in the expansion of its GMP-production capacities. By mid 2011, the company will thus be able to produce 4kg of recombinant antibodies per year and up to 11 kg upon completion of works towards the end of 2011. In sum, additional 1400 m² of facility and office space will be created.

Dr. Steffen Goletz, founder and CEO of Glycotope GmbH comments: “In particular the expansion of our DSP (Downstream Processing) capacities now places us among the top providers of GMP-production for recombinant proteins and in particular antibodies in Germany”.

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous